» Articles » PMID: 38069412

Laser-Synthesized Elemental Boron Nanoparticles for Efficient Boron Neutron Capture Therapy

Abstract

Boron neutron capture therapy (BNCT) is one of the most appealing radiotherapy modalities, whose localization can be further improved by the employment of boron-containing nanoformulations, but the fabrication of biologically friendly, water-dispersible nanoparticles (NPs) with high boron content and favorable physicochemical characteristics still presents a great challenge. Here, we explore the use of elemental boron (B) NPs (BNPs) fabricated using the methods of pulsed laser ablation in liquids as sensitizers of BNCT. Depending on the conditions of laser-ablative synthesis, the used NPs were amorphous (a-BNPs) or partially crystallized (pc-BNPs) with a mean size of 20 nm or 50 nm, respectively. Both types of BNPs were functionalized with polyethylene glycol polymer to improve colloidal stability and biocompatibility. The NPs did not initiate any toxicity effects up to concentrations of 500 µg/mL, based on the results of MTT and clonogenic assay tests. The cells with BNPs incubated at a B concentration of 40 µg/mL were then irradiated with a thermal neutron beam for 30 min. We found that the presence of BNPs led to a radical enhancement in cancer cell death, namely a drop in colony forming capacity of SW-620 cells down to 12.6% and 1.6% for a-BNPs and pc-BNPs, respectively, while the relevant colony-forming capacity for U87 cells dropped down to 17%. The effect of cell irradiation by neutron beam uniquely was negligible under these conditions. Finally, to estimate the dose and regimes of irradiation for future BNCT in vivo tests, we studied the biodistribution of boron under intratumoral administration of BNPs in immunodeficient SCID mice and recorded excellent retention of boron in tumors. The obtained data unambiguously evidenced the effect of a neutron therapy enhancement, which can be attributed to efficient BNP-mediated generation of α-particles.

Citing Articles

Boron Nanocomposites for Boron Neutron Capture Therapy and in Biomedicine: Evolvement and Challenges.

Ahmad F Biomater Res. 2025; 29:0145.

PMID: 40008112 PMC: 11850861. DOI: 10.34133/bmr.0145.


Current Insights into the Radiobiology of Boron Neutron Capture Therapy and the Potential for Further Improving Biological Effectiveness.

Punshon L, Fabbrizi M, Phoenix B, Green S, Parsons J Cells. 2025; 13(24.

PMID: 39768156 PMC: 11674336. DOI: 10.3390/cells13242065.


Laser synthesis of nanoparticles in organic solvents - products, reactions, and perspectives.

Fromme T, Reichenberger S, Tibbetts K, Barcikowski S Beilstein J Nanotechnol. 2024; 15:638-663.

PMID: 38887526 PMC: 11181208. DOI: 10.3762/bjnano.15.54.

References
1.
Kabashin A, Delaporte P, Pereira A, Grojo D, Torres R, Sarnet T . Nanofabrication with pulsed lasers. Nanoscale Res Lett. 2010; 5(3):454-63. PMC: 2894200. DOI: 10.1007/s11671-010-9543-z. View

2.
Kanygin V, Kichigin A, Zaboronok A, Kasatova A, Petrova E, Tsygankova A . In Vivo Accelerator-Based Boron Neutron Capture Therapy for Spontaneous Tumors in Large Animals: Case Series. Biology (Basel). 2022; 11(1). PMC: 8773183. DOI: 10.3390/biology11010138. View

3.
Faiao-Flores F, Coelho P, Toledo Arruda-Neto J, Camillo M, Maria-Engler S, Rici R . Boron uptake in normal melanocytes and melanoma cells and boron biodistribution study in mice bearing B16F10 melanoma for boron neutron capture therapy. Radiat Environ Biophys. 2012; 51(3):319-29. DOI: 10.1007/s00411-012-0416-y. View

4.
Goodman J, Yang W, Barth R, Gao Z, Boesel C, Staubus A . Boron neutron capture therapy of brain tumors: biodistribution, pharmacokinetics, and radiation dosimetry sodium borocaptate in patients with gliomas. Neurosurgery. 2000; 47(3):608-21; discussion 621-2. DOI: 10.1097/00006123-200009000-00016. View

5.
Zavjalov E, Zaboronok A, Kanygin V, Kasatova A, Kichigin A, Mukhamadiyarov R . Accelerator-based boron neutron capture therapy for malignant glioma: a pilot neutron irradiation study using boron phenylalanine, sodium borocaptate and liposomal borocaptate with a heterotopic U87 glioblastoma model in SCID mice. Int J Radiat Biol. 2020; 96(7):868-878. DOI: 10.1080/09553002.2020.1761039. View